Personalized medicine in psychiatry
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Personalized medicine is a model in which a patient's unique clinical, genetic, and environmental characteristics are the basis for treatment and prevention. Aim, method, and results: This review aims to describe the current tools, phenomenological features, clinical risk factors, and biomarkers used to provide personalized medicine. Furthermore, this study describes the target areas in which they can be applied including diagnostics, treatment selection and response, assessment of risk of side-effects, and prevention. DISCUSSION AND CONCLUSION: Personalized medicine in psychiatry is challenged by the current taxonomy, where the diagnostic categories are broad and great biological heterogeneity exists within each category. There is, thus, a gap between the current advanced research prospects and clinical practice, and the current taxonomy is, thus, a poor basis for biological research. The discussion proposes possible solutions to narrow this gap and to move psychiatric research forward towards personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys
Kessler, R. C., McLaughlin, K. A., Green, J. G., Gruber, M. J., Sampson, N. A., Zaslavsky, A. M., Aguilar-Gaxiola, S., Alhamzawi, A. O., Alonso, J., Angermeyer, M., et al. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080499 · Cited by 2,640
Meta-analysis of the heritability of human traits based on fifty years of twin studies
Polderman, T. J. C., Benyamin, B., de Leeuw, C. A., Sullivan, P. F., van Bochoven, A., Visscher, P. M., & Posthuma, D. (2015) · Nature Genetics · doi:10.1038/ng.3285 · Cited by 2,467
Varese, F., Smeets, F., Drukker, M., Lieverse, R., Lataster, T., Viechtbauer, W., Read, J., van Os, J., & Bentall, R. P. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs050 · Cited by 2,436
Schizophrenia as a Complex Trait: Evidence From a Meta-analysis of Twin Studies
Sullivan, P. F., Kendler, K. S., & Neale, M. C. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1187 · Cited by 2,356
Strimbu, K., & Tavel, J. A. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833ed177 · Cited by 2,062
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 1×
“However, in a recent study, a sub-group of patients with major depression and high-sensitive C-reactive protein (CRP) above 5mg/L improved compared to placebo when treated with the anti-inflammatory agent infliximab, whereas those with a CRP below 5mg/L did not (24).”
Psychiatric GWAS Consortium Bipolar Disorder Working Group, Sklar, P., Ripke, S., Scott, L. J., Andreassen, O. A., Cichon, S., Craddock, N., Edenberg, H. J., Nurnberger, J. I., Rietschel, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.943 · Cited by 1,344
Sex differences in autism spectrum disorders
Werling, D. M., & Geschwind, D. H. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835ee548 · Cited by 1,245
The Prodromal Phase of First-episode Psychosis: Past and Current Conceptualizations
Yung, A. R., & McGorry, P. D. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.353 · Cited by 1,168 · cited 1×
“The prodromal phase in schizophrenia is well described (79), as is mild cognitive incline in dementia (80).”
BackgroundRegier, D. A., Narrow, W. E., Clarke, D. E., Kraemer, H. C., Kuramoto, S. J., Kuhl, E. A., & Kupfer, D. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12070999 · Cited by 1,163 · cited 2×
“Further, field trials have revealed poor reliability of the DSM-5 diagnosis of major depression, hampering consistent research findings (9).”
BackgroundA mega-analysis of genome-wide association studies for major depressive disorder
Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M., Breen, G., Byrne, E. M., Blackwood, D. H. R., Boomsma, D. I., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.21 · Cited by 1,120
Kelly, J. R., Kennedy, P. J., Cryan, J. F., Dinan, T. G., Clarke, G., & Hyland, N. P. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00392 · Cited by 1,110
Kapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
A meta-analysis of structural brain abnormalities in PTSD
KARL, A., SCHAEFER, M., MALTA, L., DORFEL, D., ROHLEDER, N., & WERNER, A. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.03.004 · Cited by 881 · cited 1×
“However, hippocampus reduction is also not specific for major depression as it has also been found in schizophrenia and post-traumatic stress disorder (45).”
BackgroundMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Lorenzetti, V., Allen, N. B., Fornito, A., & Yücel, M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.021 · Cited by 553
Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders
Psychiatric GWAS Consortium Coordinating Committee (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091354 · Cited by 450
Bekker, M. H. J., & van Mens-Verhulst, J. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80057-x · Cited by 362
Sanders, A. R., Duan, J., Levinson, D. F., Shi, J., He, D., Hou, C., Burrell, G. J., Rice, J. P., Nertney, D. A., Olincy, A., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07101573 · Cited by 349
The role of the innate immune system in psychiatric disorders
Jones, K. A., & Thomsen, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.10.002 · Cited by 274
Scott, J., Leboyer, M., Hickie, I., Berk, M., Kapczinski, F., Frank, E., Kupfer, D., & McGorry, P. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.110858 · Cited by 260
Guastella, A. J., & Hickie, I. B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.028 · Cited by 223
Papakostas, G. I., Shelton, R. C., Kinrys, G., Henry, M. E., Bakow, B. R., Lipkin, S. H., Pi, B., Thurmond, L., & Bilello, J. A. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.166 · Cited by 180 · cited 1×
“Despite extensive research to find valid biomarkers to guide diagnostics, the only commercial biological test for clinical use in psychiatric disorders found to date is the major depressive disorder score which augments standardized diagnostic interviews in identifying people with major depression (46,47).”
BackgroundThe effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178
Li, C.-T., Bai, Y.-M., Huang, Y.-L., Chen, Y.-S., Chen, T.-J., Cheng, J.-Y., & Su, T.-P. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.086983 · Cited by 177
Neuroimaging-based biomarkers for treatment selection in major depressive disorder
Dunlop, B. W., & Mayberg, H. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/bdunlop · Cited by 127 · cited 1×
“Despite many attempts to find a biological marker to guide treatment selection and response, no study to date has been able to find a biomarker ready to be implemented in clinical settings (51,52), although many, especially biochemical and neuroimaging biomarkers, has been proposed (39,40,53,54).”
BackgroundA Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
Feifel, D., Shilling, P. D., & MacDonald, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.025 · Cited by 110
Predictors of excellent response to lithium: results from a nationwide register-based study
Kessing, L. V., Hellmund, G., & Andersen, P. K. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834a5cd0 · Cited by 68
Self-citation
Cited by
Genetic modulation of oxytocin sensitivity: A pharmacogenetic approach
Chen, F. S., Kumsta, R., Dvorak, F., Domes, G., Yim, O. S., Ebstein, R. P., & Heinrichs, M. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.163 · Cited by 59
Menke, A. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s146110 · Cited by 41
“Implementing these RDocs into biomarker research is now progressively evolving (Figure 1).(15)”
MethodToward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data
Post, R. M., Goldstein, B. I., Birmaher, B., Findling, R. L., Frey, B. N., DelBello, M. P., & Miklowitz, D. J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.025 · Cited by 31
“It is increasingly clear that inadequately treated bipolar disorder is a progressive illness with stresses, episodes, and bouts of substance abuse accumulating and sensitizing, likely by epigenetic mechanisms (Hoeksema and de Winther, 2016; Post, 2016; Wium-Andersen et al., 2017).”
Background
Metadata
- Authors
- Wium-Andersen, I. K., Vinberg, M., Kessing, L. V., & McIntyre, R. S.
- Venue
- Nordic Journal of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2016-08-26
- Volume
- 71
- Issue
- 1
- Pages
- 12-19
- ISSN
- 0029-1455 (ISSN-L)
- 0803-9488
- 1502-4725
- OpenAlex
- W2507671672
- Cited by
- 74
- References
- 30
- FWCI
- 35.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.